December 8th, Yasuhiro Pharmaceuticals(002773) issued an announcement stating that Conbercept ophthalmic injection has been included in the "National Basic Medical Insurance" .The drug is listed as a Category B drug in the " National Respiratory Health Insurance and Work Injury Insurance Drug Catalog (2025)". This decision, issued by the National Healthcare Security Administration on December 7, 2025, signifies official recognition of the drug's importance in the treatment of retinal diseases.

Conbercept ophthalmic injection is currently the only domestically produced innovative drug in the catalog that covers all four major indications for fundus diseases.The company stated that inclusion in the national medical insurance catalog will improve the stability and accessibility of medication for patients. Simultaneously, the company is actively conducting Phase III clinical trials of its high-dose version of Conbercept, as well as clinical trials of gene therapy drugs KH631 and KH658 in both China and the United States. The new version of the National Reimbursement Drug List will be implemented from January 1, 2026, but its specific impact on the company's current operating performance cannot yet be accurately estimated.

In the first three quarters of 2025, Kanghong Pharmaceutical achieved revenue of 3.624 billion yuan and net profit attributable to the parent company of 1.033 billion yuan.

https://finance.eastmoney.com/a/202512083584751648.html